Particle Sciences Invests in Commercialization Expertise
CLEVELAND, Ohio, Mar 26, 2019 - (ACN Newswire) - The Lubrizol Corporation announces its contract development and manufacturing organization (CDMO), Particle Sciences, a Lubrizol LifeSciences company, has appointed Karen Bossert as vice president of operations as part of its ongoing strategy to grow and enhance its manufacturing capabilities.
Bossert's role will be key to developing and expanding Particle Sciences' clinical trial and commercial drug manufacturing services following the recent launch of its 5,000 sq. ft commercial drug product manufacturing facility at its site in Bethlehem, PA, which is also home to its drug development operations. She brings three decades of experience in pharmaceutical manufacturing operations to the organization, specializing in aseptic processing, lyophilization and commercial scale operations. Bossert previously held roles as vice president for Lyophilization Technology Inc., quality assurance and operations director for Regeneron Pharmaceuticals and commercial manufacturing manager for Smithkline Beecham Pharmaceuticals.
Barbara Morgan, general manager, at Particle Sciences states, "It's a pleasure to welcome Karen on board at this exciting time for our business as our new commercial facility becomes fully operational, driving growth in our commercial manufacturing capabilities as well as expanding our offering in the clinical trial manufacturing space. Karen will oversee the operations of the engineering team and the clinical trial and commercial manufacturing groups. With her vast industry experience, she will be key to bringing the same standard of excellence associated with our complex formulation development work into our commercial drug product manufacturing offering."
Particle Sciences has also continued to invest in equipment and software by purchasing a dedicated pre-filled syringe filler for both clinical and commercial manufacturing and purchasing and validating a Waters NuGenesis Laboratory and Secure Data Management System to further enhance the compliance of laboratory systems. The new facility was built to accommodate the production of complex sterile and non-sterile finished drugs, such as injectables and lyophilized drugs. It forms part of a wider investment by Lubrizol LifeSciences to strengthen its key capabilities, focusing on new product solutions, capacity expansion and additional commercial manufacturing.
Over the last three years Particle Sciences has grown its workforce and will continue to grow the team as it expands and develops its manufacturing capabilities.
For further information, please visit: particlesciences.com
About Particle Sciences
Particle Sciences, a Lubrizol LifeSciences company, is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and innovative medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2018 were $6.8 billion. For more information, visit Lubrizol.com.
Media Contacts Ben Patti (216) 447-5827 [email protected] www.lubrizol.com/LifeSciences
###
This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Lubrizol via Globenewswire
Source: Lubrizol
Copyright ©2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Press Release
 Low Carbon on Cement Possible with CCS Jan 22, 2021 09:04 JST
|  MHIET Conducts Combustion Test for Hydrogen Engine with Pure Hydrogen Jan 21, 2021 17:38 JST
|  Fujitsu Delivers Cashless, Contactless Retail Experience for Masked Shoppers with Hygienic, Multi-Factor Biometric Authentication Technology Jan 21, 2021 10:05 JST
|  Honda, Cruise and GM Take Next Steps Toward Autonomous Vehicle Mobility Service Business in Japan Jan 20, 2021 11:29 JST
|  DENSO Collaborates with Aeva to Bring New LiDAR to Market Jan 20, 2021 09:34 JST
|  Mitsubishi Corporation: Commercial Operations Commence at Methanol / Dimethyl Ether Plant in Trinidad and Tobago Jan 19, 2021 10:25 JST
|  TOYOTA GAZOO Racing Targets the Top Step on Classic Season Opener Jan 18, 2021 18:08 JST
|  Second Overall as Toyota Gazoo Racing Fights To the End of Dakar 2021 Jan 18, 2021 17:30 JST
| SDK to increase capacity of aluminum substrate for hard disks Jan 15, 2021 10:00 JST
|  Toyota Gazoo Racing Introduces GR010 Hybrid Hypercar  Jan 15, 2021 08:37 JST
|  New-Look Toyota Yaris Wrc Ready to Fight for More Titles in 2021 Jan 15, 2021 08:16 JST
|  NEC Concludes Contract to Supply the Palau Cable 2 (PC2) Optical Submarine Cable Jan 14, 2021 14:01 JST
|  Fujitsu Leverages Deep Learning to Achieve World's Most Accurate Recognition of Complex Actions and Behaviors Based on Skeleton Data Jan 13, 2021 10:55 JST
|  Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium Jan 12, 2021 12:37 JST
|  Thailand's First Demonstration Project of Optimized Performance Enabling Network for Volt/Var(Q) (OPENVQ) in Power Transmission Networks Jan 12, 2021 12:21 JST
|  NEC Releases 'WISE VISION Endoscopy' in Europe and Japan Jan 12, 2021 10:56 JST
| ![Norwegian Block Exchange [NBX]](http://www.jcnnewswire.com/image/toppage/NBX.Small.Logo.48.jpg) Norwegian Block Exchange (NBX) Raises Capital for Growth Jan 12, 2021 07:30 JST
|  MHI Thermal Systems Receives 2020 "Agency for Natural Resources and Energy Commissioner's Award" for MSV2 Series of High-efficiency, Air-cooled Heat Pump Chillers Jan 07, 2021 15:20 JST
|  Olympus and Hitachi Announce Long-Term Business Alliance regarding Endoscopic Ultrasound Systems Jan 06, 2021 18:48 JST
|  Hitachi Automotive Systems, Keihin, Showa, and Nissin Kogyo Conclude Management Integration and Commence Operations as Hitachi Astemo Jan 06, 2021 18:17 JST
|
More Latest Release >>
|